Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
- Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus
Oral presentation:
Title: Lonafarnib Combination with Peginterferon Lambda Diminished Triphasic HDV Kinetic Pattern
Seen Under Lambda Monotherapy: the LIFT-1 HDV Study
Authors: Duehren, S.; Heller, T. et al.
Session: Hepatitis B Emerging Therapies
Date & Time:
Abstract #: 1904
Presenter:
Poster presentations:
Title: Strong Correlation Between HBsAg, ALT and HDV-RNA Levels in Patients with Chronic Hepatitis
Delta: Results of Phase 3 D-LIVR Study
Authors: Buti, M.; Lampertico, P. et al.
Session: Viral Hepatitis A, B, C, D, E: Virology
Date & Time:
Abstract #: 3494
Title: Clinical Features Predictive of Cirrhosis in a Large Cohort of Patients with Chronic Hepatitis Delta Infection - Insights from the D-LIVR Trial
Authors: Etzion, O.; Lampertico, P. et al.
Session: Viral Hepatitis B/D: Clinical Aspects Except Therapy
Date & Time:
Abstract #: 3442
Title: Mathematical Modeling of HDV RNA Kinetics Suggests High Peginterferon Lambda Efficacies in Blocking Viral Production and Infection: Insights from the LIMT-1 Study
Authors: Cardozo-Ojeda,, E.F.; Etzion, O. et al
Session: Viral Hepatitis B/D: Therapy
Date & Time:
Abstract #: 2072
Additional Congress Activities:
Event: 21st Hepatitis Delta International Network
Presentation Title: Lonafarnib and Peginterferon Lambda: Monotherapy and Combination Treatments in
Date & Time:
Location: ExCel
Presenter: Ingrid Choong, Ph.D., SVP, Clinical Development Eiger BioPharmaceuticals
Event: Eiger Booth #101
Date & Time:
Event: Eiger Reception for Investigators, Investors and Analysts
Date:
Location:
All five
For additional information about
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]
Media:
Sarah Mathieson
SVP, Corporate Affairs
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-multiple-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022-301563811.html
SOURCE